Presenting at the Maxim Group Growth Conference (7913Z)

TIDMMEDG TIDMMEDU

RNS Number : 7913Z

Medgenics Inc

21 March 2012

 
Press Release  21 March 2012

Medgenics, Inc.

("Medgenics" or the "Company")

MEDGENICS TO PRESENT AT THE MAXIM GROUP GROWTH CONFERENCE

Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics, will present a corporate overview and update at the Maxim Group Growth Conference being held on Monday, March 26, 2012 at The Grand Hyatt Hotel, Grand Central Station, New York. Dr. Pearlman will deliver his presentation on March 26 at 10:30 a.m. Eastern time.

The presentation will be webcast live and archived online at the Investors section of the Company's website at www.medgenics.comand at http://wsw.com/webcast/max4/mdgn/ .

About Medgenics

Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia. Medgenics believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins.

Medgenics has three long-acting protein therapy products in development based on this technology:

   --     EPODURE (now completing a Phase I/II dose-ranging trial) to produce and deliver erythropoietin for many months from a single administration, has demonstrated elevation and stabilization of hemoglobin levels in anemic patients for six to more than 36 months;

-- INFRADURE (planning to commence a Phase I/II trial in Israel in 1H12 in hepatitis C) to produce a sustained therapeutic dose of interferon-alpha for use in the treatment of hepatitis;

   --     HEMODURE is a sustained Factor VIII therapy for the prophylactic treatment of hemophilia, now in development.

Medgenics intends to develop its innovative products and bring them to market via strategic partnerships with major pharmaceutical and/or medical device companies.

In addition to treatments for anemia, hepatitis and hemophilia, Medgenics plans to develop and/or out-license a pipeline of future Biopump(TM) products targeting the large and rapidly growing global protein therapy market, which is forecast to reach $132 billion in 2013. Other potential applications for Biopumps(TM) include multiple sclerosis, arthritis, pediatric growth hormone deficiency, obesity and diabetes.

Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend, " "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

For further information, contact:

 
      Medgenics, Inc.                        Phone: +972 4 902 8900 
       Dr. Andrew L. Pearlman 
       andrew.pearlman@medgenics.com 
 
       LHA                                    Phone: 212-838-3777 
       Anne Marie Fields 
       afields@lhai.com 
       @LHA_IR_PR 
      Abchurch Communications                Phone: +44 207 398 
       Adam Michael                           7719 
       Joanne Shears 
       Jamie Hooper 
       jamie.hooper@abchurch-group.com 
      Religare Capital Markets (UK) Limited  Phone: +44 207 444 
       (NOMAD)                                0542 
       David Porter, Richard Thompson 
      SVS Securities plc (Joint Broker)      Phone: +44 207 638 
       Alex Mattey                            5600 
       Ian Callaway 
      Nomura Code Securities (Joint Broker)  Phone: +44 207 776 
       Jonathan Senior                        1219

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCJBMTTMBATBTT

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024